BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
July 23, 2012 at 07:45 AM EDT
Mentor Capital Cancer Immunotherapy Index Gains 29% During First Half of 2012

Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index has appreciated 28.7% during the first half of 2012. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first half the biotech indices averaged a 30.7% gain. In comparison, during the first six months of 2012, the Dow, S&P 500 and NASDAQ Composite indices appreciated 5.42%, 8.31% and 12.66%, respectively.

Immunocellular Therapeutics (176%), Agenus (162%) and Celldex (99%) have led the sector in gains during the January thru June 2012 period. Cancer immunotherapy pioneer, Dendreon, dominates the market capitalization of the sector, representing 49% of the combined Cancer Immunotherapy Index total share value of $2.3 Billion.

The Mentor Capital Cancer Immunotherapy Index companies and their reported first half 2012 gains follow: Dendreon (NASDAQ:DNDN) -2.63%, Immunocellular Therapeutics, Ltd. (AMEX:IMUC) +175.74%, Agenus (NASDAQ:AGEN) +162.00%, Oncothyreon (NASDAQ:ONTY) -38.26%, Biovest International (BVTI.PK) +9.33%, Celldex Therapeutics (NASDAQ:CLDX) +99.04%, Northwest Biotherapeutics (OTCBB:NWBO) -36.46%, CEL – SCI Corp. (AMEX:CVM) +31.08% , Generex Biotechnology (OTCBB:GNBT) -38.67% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) +3.70% and Advaxis, Inc. (OTCBB:ADXS) -42.02% - all for an average six month gain of +28.72% (approximately +57.44% if annualized).

Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest in leading-edge private and public cancer companies and those associated companies that reduce the cost of medical treatments. Mentor created the Cancer Immunotherapy Index July 10, 2009. Since then, it has invested or maintained a tracking position in all companies in the Cancer Immunotherapy Index. The Index company summaries can be tracked through updates of the Cancer Immunotherapy Index presented at www.MentorCapital.com.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

Contacts:

Mentor Capital, Inc.
Chester Billingsley, CEO
760-788-4700
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here